272 related articles for article (PubMed ID: 21082981)
1. Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.
Goldstein SC; Porter DL
Expert Rev Hematol; 2010 Jun; 3(3):301-14. PubMed ID: 21082981
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation.
Foss FM
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S35-43. PubMed ID: 16549113
[TBL] [Abstract][Full Text] [Related]
4. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation.
Champlin R; Khouri I; Anderlini P; Gajewski J; Kornblau S; Molldrem J; Shimoni A; Ueno N; Giralt S
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S13-22. PubMed ID: 11436116
[TBL] [Abstract][Full Text] [Related]
5. Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.
Mohty M; Fegueux N; Exbrayat C; Lu ZY; Legouffe E; Quittet P; Lopez-Martinez E; Latry P; Avinens O; Hertog C; Klein B; Eliaou JF; Rossi JF
Bone Marrow Transplant; 2001 Aug; 28(4):335-9. PubMed ID: 11571504
[TBL] [Abstract][Full Text] [Related]
6. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance.
Kline J; Subbiah S; Lazarus HM; van Besien K
Bone Marrow Transplant; 2008 Mar; 41(6):505-13. PubMed ID: 18026144
[TBL] [Abstract][Full Text] [Related]
7. Update on non-myeloablative stem cell transplantation for hematologic malignancies.
Giralt S
Int J Hematol; 2002 Aug; 76 Suppl 1():368-75. PubMed ID: 12430884
[TBL] [Abstract][Full Text] [Related]
8. Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
Handgretinger R; Kurtzberg J; Egeler RM
Pediatr Clin North Am; 2008 Feb; 55(1):71-96, x. PubMed ID: 18242316
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
10. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
11. New approaches to treating malignances with stem cell transplantation.
Margolis J; Borrello I; Flinn IW
Semin Oncol; 2000 Oct; 27(5):524-30. PubMed ID: 11049020
[TBL] [Abstract][Full Text] [Related]
12. Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation.
Sangiolo D; Mesiano G; Carnevale-Schianca F; Piacibello W; Aglietta M; Cignetti A
Expert Opin Biol Ther; 2009 Jul; 9(7):831-40. PubMed ID: 19463075
[TBL] [Abstract][Full Text] [Related]
13. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
14. [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review].
Cheng YC; Ueno NT
Nihon Rinsho; 2003 Sep; 61(9):1619-34. PubMed ID: 14515734
[TBL] [Abstract][Full Text] [Related]
15. CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.
Maury S; Lemoine FM; Hicheri Y; Rosenzwajg M; Badoual C; Cheraï M; Beaumont JL; Azar N; Dhedin N; Sirvent A; Buzyn A; Rubio MT; Vigouroux S; Montagne O; Bories D; Roudot-Thoraval F; Vernant JP; Cordonnier C; Klatzmann D; Cohen JL
Sci Transl Med; 2010 Jul; 2(41):41ra52. PubMed ID: 20650872
[TBL] [Abstract][Full Text] [Related]
16. Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.
Petrovic A; Hale G
Expert Rev Clin Immunol; 2011 Jul; 7(4):515-25; quiz 526-7. PubMed ID: 21787195
[TBL] [Abstract][Full Text] [Related]
17. Nonmyeloablative blood stem cell transplantation as adoptive allogeneic immunotherapy for metastatic renal cell carcinoma.
Childs RW
Crit Rev Immunol; 2001; 21(1-3):191-203. PubMed ID: 11642604
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
[TBL] [Abstract][Full Text] [Related]
19. Reduced intensity conditioning for allogeneic hematopoietic stem-cell transplant determines the kinetics of acute graft-versus-host disease.
Turner BE; Kambouris ME; Sinfield L; Lange J; Burns AM; Lourie R; Atkinson K; Hart DN; Munster DJ; Rice AM
Transplantation; 2008 Oct; 86(7):968-76. PubMed ID: 18852664
[TBL] [Abstract][Full Text] [Related]
20. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer?
Zöller M; Matzku S
Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
